Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ladislaia Wolff"'
Autor:
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Somatostatin analogs (SSA), specifically octreotide and lanreotide, have demonstrated antiproliferative effects in patients with neuroendocrine tumors (NET), a group of rare malignancies of diverse origin and presentation. A prominent feature of NET
Externí odkaz:
https://doaj.org/article/a945e9c944a04e59890b3ab8653e808d
Autor:
Philipp Melhorn, Elisabeth Kretschmer-Chott, Ladislaia Wolff, Alexander Haug, Peter Mazal, Markus Raderer, Barbara Kiesewetter
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Different oncological therapies have been approved for small intestinal neuroendocrine tumors (SI-NETs), but relatively little is known about efficacy and long-term outcome outside of phase III trials. Methods: This retrospective analysis
Externí odkaz:
https://doaj.org/article/091def839d3d4f219287fa4f35e93bb9
Autor:
Ladislaia Wolff, Ariane Steindl, Petar Popov, Karin Dieckmann, Brigitte Gatterbauer, Georg Widhalm, Anna Sophie Berghoff, Matthias Preusser, Markus Raderer, Barbara Kiesewetter
Publikováno v:
Clinical & Experimental Metastasis. 40:217-226
Brain metastases (BM) in patients with thyroid cancer (TC) are rare with an incidence of 1% for papillary and follicular, 3% for medullary and up to 10% for anaplastic TC (PTC, FTC, MTC and ATC). Little is known about the characteristics and manageme
Publikováno v:
memo - Magazine of European Medical Oncology. 16:47-51
SummaryEstablished systemic treatment options for advanced thyroid cancer include the multityrosine kinase inhibitors lenvatinib and sorafenib for radioactive iodine refractory differentiated thyroid cancer (DTC) and vandetanib and cabozantinib for m
Autor:
Ladislaia Wolff, Barbara Kiesewetter
Publikováno v:
memo - Magazine of European Medical Oncology. 15:190-195
SummaryScoring systems for classifying genomic alterations (GAs) with respect to their potential targeted anticancer therapies (TTs) may be useful for rational and evidence-based decision-making, for example in molecular tumor boards. Therefore, a wo